Levemir FlexPen solution for injections 100 IU/ml. 3 ml. syringe №5

Description

Levemir FlexPen Storage
active substance: 1 ml of solution for injection contains 100 IU (≈ 14.2 mg) of insulin detemir (rDNA) *;

1 pre-filled syringe handle contains 3 ml, which is equivalent to 300 IU;

1 unit (OD) of insulin detemir corresponds to 1 IU of human insulin;

excipients: glycerin; phenol; metacresol; zinc acetate, dihydrate; sodium hydrogen phosphate, dihydrate; sodium chloride; dilute hydrochloric acid, sodium hydroxide, water for injections.

* Produced by rDNA technology in Saccharomyces cerevisiae.

Levemir FlexPen Dosage form
Solution for injection.

Basic physical and chemical properties: transparent, colorless, neutral solution.

Levemir FlexPen Pharmacotherapeutic group
Drugs used in diabetes. Insulins and analogues for injection, long-acting.

Code ATX A10A E05.

Levemir FlexPen Pharmacological properties
Pharmacodynamics.

Levemir® FlexPen® is a soluble analogue of basal insulin with a prolonged profile of action, which is used as basal insulin.

The hypoglycemic effect of the drug is to promote the uptake of glucose by tissues after binding of insulin to the receptors of muscle and fat cells, as well as the simultaneous inhibition of glucose secretion from the liver.

The duration of action of Levemir® FlexPen® is statistically significantly less variable than that of the neutral protamine Hagedorn (NPH-insulin).

The prolonged action of the drug is due to the close relationship of insulin detemir molecules at the injection site and the attachment of albumin to them through the side chain of fatty acids. Compared with NPH insulin, insulin detemir is more slowly distributed in peripheral target tissues. This combined mechanism of prolongation of action causes a more predictable absorption and action profile of the drug Levemir® FlexPen® than NPH insulin.

Indication
Levemir® FlexPen® is intended for the treatment of diabetes mellitus in adults, adolescents and children over 1 year of age.

Contraindication
Hypersensitivity to insulin detemir or to any ingredient of the drug (see section “Excipients”).

Interaction with other medicinal products and other forms of interaction
It is known that a number of drugs affect glucose metabolism, which should be taken into account when determining the dose of insulin.

Medicines that can reduce the need for insulin